During the peak pandemic period, batches of a drug called Remdesivir manufactured by a Gujarat based pharma company were found to contain bacterial endotoxins which when administered to patients manifested in severe adverse
3/n events. Endotoxins are not supposed to be present in injectibles, the way to make sure your drugs are not contaminated is to run a series of tests prescribed in the Indian Pharmacopiea before you ship them the market. The Pharmacopiea sets the standards and tells us what
4/n quantities of “related substances” often called impurities are acceptable in a formulation.
As it stands now, any drug that failed standards set by the Indian Pharmacopoeia Commission would be prosecuted: ipc.gov.in
This is going to change with the new bill.
5/n
Section 56(e) of the new Bill proposes lowering punishments for drugs that have been declared "Not of Standard Quality" (NSQ) due to any of the 43 defects listed in the fourth schedule of the Bill.
Lets look at some of these defects, shall we:
6/n
Look closely at item 27 in this list; it is a catch-all term for identifying and quantifying “impurities” in your medicine. Unlike items 4 and 9, which relax the acceptable limits for what is in your medicine and how long it takes to dissolve in your gut,
7/n item 27 has NO limits specified. If this proposed law goes into effect, chances are, manufacturers of this supposed “medicine” which has contaminants like "endotoxins" will be let off with nothing more than a slap on their wrist.
8/n
Why did the committee which drafted this law do this?
The answer is simple, the pharma industry asked for it and the drafting committee agreed to do so.
9/n
Look closely at who organized this meeting. Its @nppa_india , which falls under the Dept. of Pharmaceuticals. And what was the purpose of the meeting?
And so, to make it easier to “do business” the @MoHFW_INDIA sets up a panel which
10/n
recommends “removal of penal provisons where a drug or a medical device has no harmed a patient”
And so, the expert committee drafts this amendment which goes way beyond what was recommended by the panel.
12/n
The bare reading of the proposed amendment takes penal provisions out for all kinds of failures, including those that result in bodily harm to patients. Go figure!
13/n
And now for the icing on the cake:
14/n “Compounding” means the prosecuting drug controller has the discretion to waive a trial and prison time as long as the accused pharmaceutical company agrees to pay the fine. In effect, the industry has achieved its goal of total “decriminalization”.
15/n And, if this wasn’t bad enough, look at what else is in the proposed amendment:
16/n The administration will have the power, if this amendment becomes the law to expand the list of exceptions in the fourth schedule.
Any bets on how long that will eventually be?
17/n
If there is one reason why the Minister @OfficeOf_MM should just junk this amendment and get an independent group of experts to advise him on what really is needed to reform the Drugs and Cosmetics Act, this is it.
Over the last couple of days, scandalous news of the arrest of a Joint Drug Controller in @CDSCO_INDIA_INF has made waves. While much of the reporting is perfunctory until now, it helps to peel the onion and see how far the stench
2/n
of corruption pervades the unholy nexus between the pharmaceutical industry and the DCGI’s office.
Lets start with a few facts, shall we:
A.“CBI officers claimed Bioinnovat Research Services Private Limited had been asked to get regulatory clearance for the Biocon
3/n
product. Bioinnovate, in turn, engaged Synergy Network to get the work done, the officers claimed.” indianexpress.com/article/india/…
Last week, we sent a petition to the Minister of @MoHFW_INDIA asking for the Clinical Trial Registry of India to be fixed once and for all. Here it is:
This past week has seen much name calling and hyperventilation on TV debates between the representatives of the industry which practices evidence based medicine and the spokesperson who supposedly speaks on behalf of the Ayurvedic industry.
1/n
2/n Want to know why the administration is relegated to writing love-letters pleading "withdrawal" of "objectionable" comments? @Preddy85 and I wrote about it here in the summer of last year: livemint.com/opinion/online…
3/n
Our regulation does NOT require the Ayush manufacturers to prove that their product has any therapeutic efficacy as is the case for drugs that are marketed by the pharmaceutical industry.
In fact, in 2018, the @moayush amended India’s Drugs & Cosmetics Rules, 1945
Can someone explain to me why there is no central TRIAGE of all positive cases in cities like Delhi? Let me explain what I mean
Last night, I participated in a @TwitterSpaces discussion organized by @PSampathkumarMD 1/n
2/n We had a gentleman who provides ambulance services in Delhi on the call. This question is based on what I learnt from him
Watching the tragedy unfold, the question we need is what can be done so that people who need help are not left waiting to get the care they need.
3/n Why do we make people run around pillar to post to look for beds?
Large cities like Delhi need to set up a central triage where a group of physicians evaluate every positive case and determine:
1.If the patient can be cared for at home with assistance
This clip is a good example of why it is important to screen your panelists before putting them on. 1/n
Dr. Joshi says that he uses Remdesivir to treat moderate and severe disease; and makes broad statements like the drug is recommend by @US_FDA.
2/n Look up what *moderate* and *severe* mean in this context. The other panelist, Dr Parikh provides a history lesson on how this drug came to be used for treating Covid-19; how relevant that is to the question being discussed is anyone's guess.
3/n Remdesivir has a role in treating the disease in a narrow population demographic and at a very specific stage in disease progression. Here is the current clinical evidence: altnews.in/remdesivir-is-…
Clinicians like Dr Joshi dont seem to give very little weight to such evidence
This is a limited point about availability of efficacy data for vaccines under development in the context of the approval for CovidShield and Covaxin in India.
There have been many so-called experts on the idiotbox opining about apparent availability of P III data which 1/n
2/n apparently the SEC had access to based on which it "supposedly" approved Covaxin. Another argument that is prevalent is other regulators (US FDA and MHRA) also approved vaccines based on P II data alone. Let me give you a few facts so that you can make your own decision.
3/n The protocols for both mRNA vaccines are publicly available. You can check. Both protocols *define* when the interim analysis will be done. This is not subjective. They clearly define how many infections need to be documented before the Data Safety Monitoring Board meets.